Current Infectious Disease Reports

, Volume 15, Issue 5, pp 364–371

Noncanonical Nuclear Factor Kappa B (NF-κB) Signaling and Potential for Therapeutics in Sepsis

Sepsis and ICU (J Russell, Section Editor)

Abstract

NF-κB signaling plays a central role in the pathophysiology of severe sepsis and septic shock. Despite tremendous and missed efforts, novel therapeutics for severe sepsis and septic shock are still needed. Many drugs have been designed to target the canonical NF-κB signaling pathway with limited success, potentially due to the nonspecificity of the drugs for other kinases and the interaction of canonical signaling with other pathways. Here, we review the canonical and noncanonical signaling pathways of NF-κB, the cross talk and negative regulation of the two pathways, and the potential for therapeutics arising from the noncanonical NF-κB pathway in relation to the pathophysiology of septic shock.

Keywords

Sepsis Septic shock Therapeutics Noncanonical NF-κB signaling Personalized medicine 

References

Papers of particular interest have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Angus DC et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303–10.PubMedCrossRefGoogle Scholar
  2. 2.
    Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3(9):745–56.PubMedCrossRefGoogle Scholar
  3. 3.
    Levy MM et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31(4):1250–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Aggarwal BB et al. Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line. J Biol Chem. 1985;260(4):2334–44.PubMedGoogle Scholar
  5. 5.
    Aggarwal BB, Moffat B, Harkins RN. Human lymphotoxin. Production by a lymphoblastoid cell line, purification, and initial characterization. J Biol Chem. 1984;259(1):686–91.PubMedGoogle Scholar
  6. 6.
    Aggarwal BB et al. Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem. 1985;260(4):2345–54.PubMedGoogle Scholar
  7. 7.
    Tracey KJ et al. Shock and tissue injury induced by recombinant human cachectin. Science. 1986;234(4775):470–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Tracey KJ et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330(6149):662–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Aggarwal BB, Eessalu TE, Hass PE. Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature. 1985;318(6047):665–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25(6):280–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Hsu H et al. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 1996;84(2):299–308.PubMedCrossRefGoogle Scholar
  12. 12.
    Yeh WC et al. Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity. 1997;7(5):715–25.PubMedCrossRefGoogle Scholar
  13. 13.
    Nakano H et al. Targeted disruption of Traf5 gene causes defects in CD40- and CD27-mediated lymphocyte activation. Proc Natl Acad Sci U S A. 1999;96(17):9803–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Tada K et al. Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death. J Biol Chem. 2001;276(39):36530–4.PubMedCrossRefGoogle Scholar
  15. 15.
    Blonska M et al. TAK1 is recruited to the tumor necrosis factor-alpha (TNF-alpha) receptor 1 complex in a receptor-interacting protein (RIP)-dependent manner and cooperates with MEKK3 leading to NF-kappaB activation. J Biol Chem. 2005;280(52):43056–63.PubMedCrossRefGoogle Scholar
  16. 16.
    DiDonato JA et al. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature. 1997;388(6642):548–54.PubMedCrossRefGoogle Scholar
  17. 17.
    Lee FS et al. Activation of the IkappaB alpha kinase complex by MEKK1, a kinase of the JNK pathway. Cell. 1997;88(2):213–22.PubMedCrossRefGoogle Scholar
  18. 18.
    Li Q et al. IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev. 1999;13(10):1322–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Cohen L, Henzel WJ, Baeuerle PA. IKAP is a scaffold protein of the IkappaB kinase complex. Nature. 1998;395(6699):292–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Huxford T et al. The crystal structure of the IkappaBalpha/NF-kappaB complex reveals mechanisms of NF-kappaB inactivation. Cell. 1998;95(6):759–70.PubMedCrossRefGoogle Scholar
  21. 21.
    Jacobs MD, Harrison SC. Structure of an IkappaBalpha/NF-kappaB complex. Cell. 1998;95(6):749–58.PubMedCrossRefGoogle Scholar
  22. 22.
    Malek S et al. X-ray crystal structure of an IkappaBbeta x NF-kappaB p65 homodimer complex. J Biol Chem. 2003;278(25):23094–100.PubMedCrossRefGoogle Scholar
  23. 23.
    Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000;18:621–63.PubMedCrossRefGoogle Scholar
  24. 24.
    Malinin NL et al. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature. 1997;385(6616):540–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Ling L, Cao Z, Goeddel DV. NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. Proc Natl Acad Sci U S A. 1998;95(7):3792–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Xiao G, Sun SC. Negative regulation of the nuclear factor kappa B-inducing kinase by a cis-acting domain. J Biol Chem. 2000;275(28):21081–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Xiao G, Fong A, Sun SC. Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation. J Biol Chem. 2004;279(29):30099–105.PubMedCrossRefGoogle Scholar
  28. 28.
    Xiao G, Harhaj EW, Sun SC. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell. 2001;7(2):401–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Liao G et al. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem. 2004;279(25):26243–50.PubMedCrossRefGoogle Scholar
  30. 30.
    Qing G, Qu Z, Xiao G. Stabilization of basally translated NF-kappaB-inducing kinase (NIK) protein functions as a molecular switch of processing of NF-kappaB2 p100. J Biol Chem. 2005;280(49):40578–82.PubMedCrossRefGoogle Scholar
  31. 31.
    Senftleben U et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science. 2001;293(5534):1495–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Yin L et al. Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. Science. 2001;291(5511):2162–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Ramakrishnan P, Wang W, Wallach D. Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase. Immunity. 2004;21(4):477–89.PubMedCrossRefGoogle Scholar
  34. 34.
    O'Mahony A et al. Activation of the heterodimeric IkappaB kinase alpha (IKKalpha)-IKKbeta complex is directional: IKKalpha regulates IKKbeta under both basal and stimulated conditions. Mol Cell Biol. 2000;20(4):1170–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Zarnegar B et al. Control of canonical NF-kappaB activation through the NIK-IKK complex pathway. Proc Natl Acad Sci U S A. 2008;105(9):3503–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Bista P et al. TRAF3 controls activation of the canonical and alternative NFkappaB by the lymphotoxin beta receptor. J Biol Chem. 2010;285(17):12971–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Lawrence T et al. Possible new role for NF-kappaB in the resolution of inflammation. Nat Med. 2001;7(12):1291–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med. 2007;13(11):460–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Liew FY et al. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol. 2005;5(6):446–58.PubMedCrossRefGoogle Scholar
  40. 40.
    Dixit VM et al. Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J Biol Chem. 1990;265(5):2973–8.PubMedGoogle Scholar
  41. 41.
    Beyaert R, Heyninck K, Van Huffel S. A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. Biochem Pharmacol. 2000;60(8):1143–51.PubMedCrossRefGoogle Scholar
  42. 42.
    Cook SA et al. A20 is dynamically regulated in the heart and inhibits the hypertrophic response. Circulation. 2003;108(6):664–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2007;11(5):373–84.CrossRefGoogle Scholar
  44. 44.
    Zhang W et al. Aberrant CD40-induced NF-kappaB activation in human lupus B lymphocytes. PLoS One. 2012;7(8):e41644.PubMedCrossRefGoogle Scholar
  45. 45.
    •• Leentjens J et al. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? Am J Respir Crit Care Med. 2013;187(12):1287–93. This paper is a good review of recent advances in immunotherapy as an adjunctive treatment for sepsis. Google Scholar
  46. 46.
    •• Caldwell CC, Hotchkiss RS. The first step in utilizing immune-modulating therapies: immune status determination. Crit Care. 2011;15(1):108. This paper presents a good argument for the need to include immunostatus of a patient in order to guide personalized care in the ICU. Google Scholar
  47. 47.
    Larosa SP, Opal SM. Immune aspects of sepsis and hope for new therapeutics. Curr Infect Dis Rep. 2012;14(5):474–83.PubMedCrossRefGoogle Scholar
  48. 48.
    Cheng X et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol. 2008;127(1):89–97.PubMedCrossRefGoogle Scholar
  49. 49.
    Jin W et al. Regulation of Th17 cell differentiation and EAE induction by MAP3K NIK. Blood. 2009;113(26):6603–10.PubMedCrossRefGoogle Scholar
  50. 50.
    Venet F et al. Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (−)) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med. 2009;35(4):678–86.PubMedCrossRefGoogle Scholar
  51. 51.
    Monneret G et al. Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med. 2003;31(7):2068–71.PubMedCrossRefGoogle Scholar
  52. 52.
    Venet F et al. Regulatory T cell populations in sepsis and trauma. J Leukoc Biol. 2008;83(3):523–35.PubMedCrossRefGoogle Scholar
  53. 53.
    • Tatura R et al. Quantification of regulatory T cells in septic patients by real-time PCR-based methylation assay and flow cytometry. PLoS One. 2012;7(11):e49962. This paper demonstrates a novel technique to use an epigenetic marker to distinguish Tregs from non- regulatory T cells regardless of activation status, tested on septic patient samples. Google Scholar
  54. 54.
    • Wu HP, et al. Associations of T helper 1, 2, 17 and regulatory T lymphocytes with mortality in severe sepsis. Inflamm Res. 2013. This paper investigates the relationship of Treg and Th17 cells with mortality in severe sepsis and shows an association of high Th17 counts with survival. Google Scholar
  55. 55.
    • Murray SE et al. NF-kappaB-inducing kinase plays an essential T cell-intrinsic role in graft-versus-host disease and lethal autoimmunity in mice. J Clin Invest. 2011;121(12):4775–86. This paper shows that suppression of NIK is beneficial in graft versus host disease models, characterized by increased Tregs. Google Scholar
  56. 56.
    • Thair SA et al. A single nucleotide polymorphism in NF-kappaB inducing kinase is associated with mortality in septic shock. J Immunol. 2011;186(4):2321–8. This paper shows a single nucleotide polymorphism in NIK is associated with mortality in septic shock patients and suggests that patients with the allele associated with increased mortality may have reduced levels of NIK. Google Scholar
  57. 57.
    Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354(6):610–21.PubMedCrossRefGoogle Scholar
  58. 58.
    Sprung CL et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358(2):111–24.PubMedCrossRefGoogle Scholar
  59. 59.
    Annane D et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288(7):862–71.PubMedCrossRefGoogle Scholar
  60. 60.
    Bollaert PE et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med. 1998;26(4):645–50.PubMedCrossRefGoogle Scholar
  61. 61.
    Oppert M et al. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med. 2005;33(11):2457–64.PubMedCrossRefGoogle Scholar
  62. 62.
    Sprung CL et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med. 1984;311(18):1137–43.PubMedCrossRefGoogle Scholar
  63. 63.
    Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med. 1995;23(7):1294–303.PubMedCrossRefGoogle Scholar
  64. 64.
    Cronin L et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med. 1995;23(8):1430–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Keh D et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med. 2003;167(4):512–20.PubMedCrossRefGoogle Scholar
  66. 66.
    Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax. 2000;55(7):603–13.PubMedCrossRefGoogle Scholar
  67. 67.
    Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids–new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711–23.PubMedCrossRefGoogle Scholar
  68. 68.
    Grohmann U et al. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med. 2007;13(5):579–86.PubMedCrossRefGoogle Scholar
  69. 69.
    Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol. 2007;7(10):817–23.PubMedCrossRefGoogle Scholar
  70. 70.
    Eissner G, Kolch W, Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev. 2004;15(5):353–66.PubMedCrossRefGoogle Scholar
  71. 71.
    Shevach EM, Stephens GL. The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity? Nat Rev Immunol. 2006;6(8):613–8.PubMedCrossRefGoogle Scholar
  72. 72.
    Tone M et al. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci U S A. 2003;100(25):15059–64.PubMedCrossRefGoogle Scholar
  73. 73.
    Karagiannidis C et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol. 2004;114(6):1425–33.PubMedCrossRefGoogle Scholar
  74. 74.
    Su J et al. The interleukin-1 receptor-associated kinase M selectively inhibits the alternative, instead of the classical NFkappaB pathway. J Innate Immun. 2009;1(2):164–74.PubMedCrossRefGoogle Scholar
  75. 75.
    Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008;8(7):533–44.PubMedCrossRefGoogle Scholar
  76. 76.
    Flohe S et al. Influence of granulocyte-macrophage colony-stimulating factor (GM-CSF) on whole blood endotoxin responsiveness following trauma, cardiopulmonary bypass, and severe sepsis. Shock. 1999;12(1):17–24.PubMedCrossRefGoogle Scholar
  77. 77.
    Flohe S et al. Effect of granulocyte-macrophage colony-stimulating factor on the immune response of circulating monocytes after severe trauma. Crit Care Med. 2003;31(10):2462–9.PubMedCrossRefGoogle Scholar
  78. 78.
    • Meisel C et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med. 2009;180(7):640–8. This clinical trial shows that assessing the immunostatus of a patient and treating accordingly may be a clinical reality based on this data combined with future larger trials. Google Scholar
  79. 79.
    Kox WJ et al. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch Intern Med. 1997;157(4):389–93.PubMedCrossRefGoogle Scholar
  80. 80.
    Docke WD et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med. 1997;3(6):678–81.PubMedCrossRefGoogle Scholar
  81. 81.
    Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med. 1996;24(7):1125–8.PubMedCrossRefGoogle Scholar
  82. 82.
    Nakos G et al. Immunoparalysis in patients with severe trauma and the effect of inhaled interferon-gamma. Crit Care Med. 2002;30(7):1488–94.PubMedCrossRefGoogle Scholar
  83. 83.
    Keats JJ et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12(2):131–44.PubMedCrossRefGoogle Scholar
  84. 84.
    Annunziata CM et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12(2):115–30.PubMedCrossRefGoogle Scholar
  85. 85.
    • Mortier J et al. NF-kappaB inducing kinase (NIK) inhibitors: identification of new scaffolds using virtual screening. Bioorg Med Chem Lett. 2010;20(15):4515–20. This paper reveals potential small molecule inhibitors of NIK that may be useful in the treatment of multiple myeloma and if successful may lead to increased knowledge of the role of NIK in both the canonical and noncanonical NF-kB signaling pathways, which may lead to a better understanding of the role of NIK in septic shock. Google Scholar
  86. 86.
    Chen G, CT., Fisher B, He X, Li K., Li Z., McGee L., Pattaropong V, Faulder P, Seganish JL, Shin y, Wang Z, Liu W. Alkynyl alcohols as kinase inhibitors. 2009.Google Scholar
  87. 87.
    Goto Y, ST., Fan W, Haxel TFN, Jenks MG, Malaska MJ, Moore JA, Ouvry G, Pandi B, Peel MR, Steward KM. Novel 6-Azainodole aminopyrimidine derivates having NIK inhibitory activity. 2010.Google Scholar
  88. 88.
    Gasparini C, Feldmann M. NF-kappaB as a target for modulating inflammatory responses. Curr Pharm Des. 2012;18(35):5735–45.PubMedCrossRefGoogle Scholar
  89. 89.
    Pettit AR et al. Differentiated dendritic cells expressing nuclear RelB are predominantly located in rheumatoid synovial tissue perivascular mononuclear cell aggregates. Arthritis Rheum. 2000;43(4):791–800.PubMedCrossRefGoogle Scholar
  90. 90.
    Martin E et al. Antigen-specific suppression of established arthritis in mice by dendritic cells deficient in NF-kappaB. Arthritis Rheum. 2007;56(7):2255–66.PubMedCrossRefGoogle Scholar
  91. 91.
    Nakada TA, et al. beta2-Adrenergic receptor gene polymorphism is associated with mortality in septic shock. Am J Respir Crit Care Med. 181(2):143–9.Google Scholar
  92. 92.
    Nakada TA et al. Association of angiotensin II type 1 receptor-associated protein gene polymorphism with increased mortality in septic shock. Crit Care Med. 2011;39(7):1641–8.PubMedCrossRefGoogle Scholar
  93. 93.
    Russell JA, Wellman H, Walley KR. Protein C rs2069912 C allele is associated with increased mortality from severe sepsis in North Americans of East Asian ancestry. Hum Genet. 2008;123(6):661–3.PubMedCrossRefGoogle Scholar
  94. 94.
    Sutherland AM et al. The association of interleukin 6 haplotype clades with mortality in critically ill adults. Arch Intern Med. 2005;165(1):75–82.PubMedCrossRefGoogle Scholar
  95. 95.
    Wattanathum A et al. Interleukin-10 haplotype associated with increased mortality in critically ill patients with sepsis from pneumonia but not in patients with extrapulmonary sepsis. Chest. 2005;128(3):1690–8.PubMedCrossRefGoogle Scholar
  96. 96.
    Wurfel MM et al. Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am J Respir Crit Care Med. 2008;178(7):710–20.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.University of British Columbia, Heart Lung Innovation Research Centre, Critical Care Research LaboratoriesSt. Paul’s HospitalVancouverCanada

Personalised recommendations